DRRX Profile
DURECT Corporation, founded in 1998 and based in Cupertino, California, operates as a biopharmaceutical company focused on advancing innovative medicines through its robust epigenetic regulator and pharmaceutical programs. The company's diverse product portfolio includes the ALZET line, featuring osmotic pumps and accessories used extensively in research involving mice, rats, and other laboratory animals.
Central to DURECT's developmental pipeline is larsucosterol (DUR-928), a promising endogenous small molecule currently in Phase IIb clinical trials. This compound is designed to regulate lipid metabolism, stress responses, inflammatory processes, and cell survival and death mechanisms. DUR-928 holds potential applications in treating alcohol-associated hepatitis, with completed Phase Ib trials demonstrating its efficacy in addressing nonalcoholic steatohepatitis.
Additionally, DURECT markets POSIMIR, an innovative post-surgical pain management product that delivers sustained-release bupivacaine for extended pain relief in adult patients. The company also offers Methydur, addressing attention deficit hyperactivity disorder, further diversifying its therapeutic offerings.
DURECT Corporation operates globally, leveraging a direct sales force in the United States and a network of distributors spanning Japan, Europe, and international markets for its ALZET product line. The company also maintains strategic collaborations with entities such as Virginia Commonwealth University Intellectual Property Foundation, Indivior UK Ltd., and Santen Pharmaceutical Co., Ltd., reinforcing its commitment to advancing cutting-edge treatments and expanding its market reach in the biopharmaceutical sector.
|
